SKOKIE, Ill.--(BUSINESS WIRE)--Vetter, a leading international contract development and manufacturing organization (CDMO) that specializes in aseptic filling for its (bio-)pharmaceutical customers, has announced today that a number of activities undertaken at its local Skokie facility to satisfy existing and ever-increasing future customer demands have been completed. The initiatives include an additional staff shift for daily manufacturing operations, as well as the doubling of capacities for performing important quality control functions.
Satisfied customer demand creates a positive business outlook
“We are extremely pleased with our past years performance at this facility, as well as our overall success to date,” said Vetter Managing Director Peter Soelkner. “Skokie, considered the ‘world’s largest Village‘, is a wonderful location, and we are very happy to be in the position of doing business here.” Since starting complete operations in late 2011, the site, located at the Illinois Science + Technology Park in suburban Chicago, has successfully passed audits and qualifications by as many as 30 companies, including 9 of the 20 world-leading (bio-)pharmaceutical companies. This performance has resulted in a wide-ranging customer base that includes not only those in the US, but also European companies based for example in the UK and Denmark, as well as Asian headquartered companies such as in South Korea.
“Many of our customers have already returned for development work for a second, third, or even fourth molecule,” added Dr. Susanne Resatz, President of Vetter Development Services USA, Inc. who is responsible for heading up the operation. “Furthermore, our outlook for future performance is very positive as demonstrated by a pipeline filled with high quality customer projects for biologics. It is heartening to know that the drugs that we are developing at this facility for our customers are then used to help people around the world.” Drugs under development by Vetter’s customers include treatments for blood cancer, muscular dystrophy, wound healing, and dwarfism.
Proven successful cooperation between the company’s Skokie and European facilities
Vetter, known as a contract development and manufacturing organization, by its nature offers its customers manufacturing resources starting from early drug development through to market launch and commercial supply. If desired, customers can begin their drug development in its early stages at the Skokie facility and then get a transfer of their drug product to one of Vetter’s European facilities for development and commercialization.
To date, four customer products in development have already been successfully passed this milestone. The company plans for additional product transfers from the US to Europe in 2015 and subsequent years.
About Vetter
Vetter is a premier contract development and manufacturing organization (CDMO) and a global leader in the fill and finish of aseptically prefilled syringe systems, cartridges and vials. Headquartered in Ravensburg, Germany, with facilities in Germany and the United States, the company provides state-of-the-art manufacturing, from early clinical development through commercial filling and packaging of parenteral drugs. The CDMO’s extensive experience covers a broad range of complex compounds, including monoclonal antibodies, peptides and interferons. Vetter supports its customers every step of the way, guiding their products through development, regulatory approval, launch and lifecycle management. Known for quality, the company offers a foundation of experience spanning more than 35 years, including dozens of product approvals for novel bio/ pharmaceutical compounds. Since 2014, Vetter operates a representative office in Singapore, increasing the presence of the company and the awareness of its service portfolio in the Asian healthcare market. Visit www.vetter-pharma.com
